Variation in Treatment of Pediatric Tuberculosis Infection in Different Provider Settings.

[1]  J. Starke,et al.  Tuberculosis Infection in Children and Adolescents: Testing and Treatment. , 2021, Pediatrics.

[2]  M. Donahue,et al.  Tele-TB: Using TeleMedicine to Increase Access to Directly Observed Therapy for Latent Tuberculosis Infection. , 2021, Military medicine.

[3]  L. Goscé,et al.  An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study , 2020, BMC Infectious Diseases.

[4]  Kaylynn Aiona,et al.  Higher Completion Rates with Self-administered Once-weekly Isoniazid-Rifapentine versus Daily Rifampin in Adults with Latent Tuberculosis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Long,et al.  Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings , 2020, Annals of Internal Medicine.

[6]  Gibril J. Njie,et al.  Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 , 2020, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[7]  J. Wortham,et al.  Epidemiology of tuberculosis among children and adolescents in the USA, 2007-17: an analysis of national surveillance data. , 2019, The Lancet. Public health.

[8]  B. Hutton,et al.  A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection , 2018, Pharmacoepidemiology and drug safety.

[9]  A. Cruz,et al.  Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens , 2018, Pediatrics.

[10]  R. Reves,et al.  Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic , 2017, The Pediatric infectious disease journal.

[11]  J. Miro,et al.  Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. , 2017, Annals of internal medicine.

[12]  T. Chorba,et al.  High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Moher,et al.  Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses , 2017, BMC Infectious Diseases.

[14]  H. Alsdurf,et al.  The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[15]  P. Polgreen,et al.  Controversies in tuberculous infection among pediatric infectious disease specialists in North America. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  T. Sterling,et al.  Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Conde,et al.  Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. , 2015, JAMA pediatrics.

[18]  C. Horsburgh,et al.  Latent tuberculous infection in the United States and Canada: who completes treatment and why? , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  J. Starke,et al.  Current Diagnosis and Treatment of Pediatric Latent Tuberculosis Infection , 2014, Current Pediatrics Reports.

[20]  K. Powell,et al.  Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. , 2011, MMWR. Morbidity and mortality weekly report.

[21]  T. Sterling,et al.  Latent TB infection treatment acceptance and completion in the United States and Canada. , 2010, Chest.

[22]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[23]  S. Lewin,et al.  Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research , 2007, PLoS medicine.